Initiated First-in-Human Trial of Novel Recombinant Bifidobacterial Anti-cancer Agent APS001F for Advanced Solid Tumors

We have initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent.

more…

Comments are closed.